BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nemluvio (nemolizumab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Nemluvio (nemolizumab)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07074977-1524@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nemluvio (nemolizumab): Phase 2 readout est. (NCT07074977)
DESCRIPTION:Nemluvio (nemolizumab)\, phase 2.\nStudy: Proof of Concept Stud
 y to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults
  With Chronic Pruritus of Unknown Origin (CPUO)\nEstimated primary complet
 ion: December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/n
 emolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07074977
URL:https://assetmemo.bio/drug/nemolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07396168-1524@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nemluvio (nemolizumab): Phase 4 readout est. (NCT07396168)
DESCRIPTION:Nemluvio (nemolizumab)\, phase 4.\nStudy: Nemolizumab to Treat 
 Lichen Planopilaris\, a Noncontrolled\, Prospective\, Pilot Study.\nEstima
 ted primary completion: June 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/nemolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07396168
URL:https://assetmemo.bio/drug/nemolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07704775-1524@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Nemluvio (nemolizumab): Phase 2 readout est. (NCT07704775)
DESCRIPTION:Nemluvio (nemolizumab)\, phase 2.\nStudy: Nemolizumab for LS\nE
 stimated primary completion: 1 September 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/nemolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07704775
URL:https://assetmemo.bio/drug/nemolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07762833-1524@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Nemluvio (nemolizumab): Phase 3 readout est. (NCT07762833)
DESCRIPTION:Nemluvio (nemolizumab)\, phase 3\, Atopic Dermatitis.\nStudy: R
 andomized\, Double-blind\, Placebo-controlled Study of Nemolizumab in Chin
 ese Subjects With Moderate-to-severe Atopic Dermatitis\nEstimated primary 
 completion: 28 October 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/nemolizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07762833
URL:https://assetmemo.bio/drug/nemolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07926867-1524@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nemluvio (nemolizumab): Phase 2/3 readout est. (NCT07926867)
DESCRIPTION:Nemluvio (nemolizumab)\, phase 2/3.\nStudy: A Pilot Multicentri
 c Open Study Assessing the Efficacy and Safety of NEMOlizumab in Patients 
 ≥ 12yo With Dystrophic Epidermolysis Bullosa\nEstimated primary completi
 on: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /nemolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07926867
URL:https://assetmemo.bio/drug/nemolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07047690-1524@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280528
DTEND;VALUE=DATE:20280529
SUMMARY:Nemluvio (nemolizumab): Phase 2 readout est. (NCT07047690)
DESCRIPTION:Nemluvio (nemolizumab)\, phase 2.\nStudy: A Study of Nemolizuma
 b for the Treatment of Adults With Systemic Sclerosis\nEstimated primary c
 ompletion: 28 May 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/nemolizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07047690
URL:https://assetmemo.bio/drug/nemolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07660835-1524@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280715
DTEND;VALUE=DATE:20280716
SUMMARY:Nemluvio (nemolizumab): Phase 2 readout est. (NCT07660835)
DESCRIPTION:Nemluvio (nemolizumab)\, phase 2\, Atopic Dermatitis.\nStudy: P
 harmacokinetics\, Safety and Efficacy of Nemolizumab in Participants Aged 
 6 to 23 Months With Moderate-to Severe Atopic Dermatitis\nEstimated primar
 y completion: 15 July 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/nemolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07660835
URL:https://assetmemo.bio/drug/nemolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07843420-1524@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Nemluvio (nemolizumab): Phase 2 readout est. (NCT07843420)
DESCRIPTION:Nemluvio (nemolizumab)\, phase 2.\nStudy: Nemolizumab for the T
 reatment of Moderate to Severe Chronic Hepatic Pruritus\nEstimated primary
  completion: November 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/nemolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07843420
URL:https://assetmemo.bio/drug/nemolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07352566-1524@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Nemluvio (nemolizumab): Phase 4 readout est. (NCT07352566)
DESCRIPTION:Nemluvio (nemolizumab)\, phase 4\, Atopic Dermatitis.\nStudy: U
 tilization of a Microdevice for Psoriasis and Atopic Dermatitis\nEstimated
  primary completion: 1 June 2030. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/nemolizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07352566
URL:https://assetmemo.bio/drug/nemolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
